euro-biopharma-ethnopharmacology-2017-keynote

3 / 13

Volume 6, Issue 4 (Suppl) Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
Page 13
Notes:
&
6th International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4th EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
Ethnopharmacology and neurodegenerative diseases: Past achievements and future expectations
Neurodegenerative diseases (NDs) cover various pathologies and associated disorders. The most known and disabling are
Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, causing motor disorders and dementia. NDs affect the
ageing population and represent one of the most challenging public health issues worldwide. The situation is particularly critical
due to the increasing number of patients, the cost of treatment, and the societal impact of day-to-day care and dependence. As
an example, around 7 million European citizens suffer fromAlzheimer's disease with a total care cost reaching 155 billion euros
each year. Besides existing drugs addressing the symptoms rather than the cause, alternative natural solutions based on natural
extracts or pure compounds are driving growing interest. This presentation begins with an overview of the current state of the
art in the use of natural resources and the products they contain, to combat the potential causes and consequences of NDs.
We will then move on to the results we have obtained in the field, by using innovative extraction technologies and controlled
biotransformation processes to enhance the effectiveness and the safety of the end products.
Jamal Ouazzani
National Center for Scientific Research CNRS, Institute for Chemistry of Natural Products ICSN,
France
Jamal Ouazzani, Clin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-024